National Wear Red Day is the first Friday in February, which coincides with National Healthy Heart Month. Wear red today and encourage your colleagues to do the same to help raise awareness that heart disease is the leading cause of death in the U.S. and is largely preventable. And, enter our Heart to Heart contest for a chance to win a $195 CMHC gift card, good on any event registration!
Enlightened practitioners of cardiology, endocrinology, renal disease, nephrology, primary care, and more turn to CMHC year after year to further their understanding of the complex relationship between these cardiometabolic disciplines. For more insights on how cardiometabolic health and whole-person medicine can break down the outdated silos of health care, attend the upcoming 18th Annual CMHC in Boston next Oct. 11-14, 2023.
"The data is requiring us to breakdown silos, to stop thinking about, “That’s not my disease; that’s not my organ,” these are shared endpoints we’re after.” – Jorge Plutzky, MD, from the 17th Annual CMHC in Boston Oct. 2022
In perhaps the biggest storyline in obesity medicine in 2023, the first-in-class medication tirzepatide may gain approval for weight loss. Read what the CMHC experts have to say on its likely approval and why it may be difficult to get it to your patients. Tirzepatide for Weight Loss
Building on the success of past webinars, CMHC is once again curating an important and timely presentation coinciding with Black History Month. With revered cardiologist Keith C. Ferdinand, MD at the helm, this February's webinar promises insights, evidence, and an honest discussion titled, Accelerating Diversity, Equity, and Inclusion in Cardiometabolic Health: Latest Updates from Leaders in the Field. Please stay tuned for an email regarding the final date and time of the webinar, and to register. In the meantime, view last year's award-winning webinar: Looming Cardiometabolic Crisis: A Conversation About Race
In the latest interview from CMHC, Expert Perspectives: Assessing the Evolving Role of GLP1-RAs to Reduce CV Risk, Drs. Aroda, Plutzky, and McDonnell, discuss novel tools including the evolving role of GLP-1RAs that can help clinicians address cardiometabolic risk, body weight, and glucose risk in a meaningful way. Recorded: Jan 10, 2023.
